A Study of EDG-7500 in Adults with Hypertrophic Cardiomyopathy (CIRRUS-HCM)

Key Inclusion Criteria:

• Male or nonpregnant female, age ≥18 years.

• Body mass index (BMI) ≥18 to <38 kg/m2; weight ≥50 kg at Screening.

• Diagnosed with hypertrophic cardiomyopathy at the time of Screening consistent withcurrent American College of Cardiology Foundation/American Heart AssociationGuidelines

• LVOT peak gradient ≥30 mmHg measured at rest and ≥50 mmHg post-Valsalva asdetermined by echocardiography at Screening (Part A, B and D oHCM only).

• LVOT peak gradient < 30 mmHg measured at rest and < 50 mmHg measured during theValsalva maneuver as determined by echocardiography as assessed by the Investigatorat Screening (Part C and D nHCM only).

• Maximal exercise peak LVOT gradient < 50 mmHg as determined by echocardiography asassessed by the Investigator (historical documentation < 12 months prior to dosingor confirmed at Screening) (Part C and D nHCM only).

• Documented left ventricular ejection fraction (LVEF) ≥0.60 at Screening.

• New York Heart Association (NYHA) Classification I-III at Screening.

Key Exclusion Criteria:

• Invasive septal reduction <180 days prior to Screening.

• Documented current or history of obstructive coronary artery disease at any time ormyocardial infarction <180 days prior to Screening.

• Known Stage B or higher aortic valve stenosis or regurgitation

• Documented current or history of cardiac amyloidosis (age ≥ 60 years requiresexclusion of cardiac amyloidosis by radionuclide scan or MRI performed at Screeningor historical scan <3 years prior to Screening).

• A history of syncope or sustained ventricular tachyarrhythmia <180 days prior toScreening.

• A history of sudden cardiac arrest at any time or known appropriate implantablecardioverter defibrillator (ICD) discharge <180 days prior to Screening

• Atrial fibrillation (AF) at Screening; a current diagnosis of permanent AF;paroxysmal or persistent AF <90 days of Screening, or electrical cardioversion orablation for AF <90 days of Screening.

• Fridericia-corrected QT interval (QTcF) ≥480 ms or any other ECG abnormalityconsidered by the Investigator to pose a risk to participant safety.

• Current or prior use of any cardiac myosin inhibitors ≥ 7.5% at the Screening Visit (Part Cand D nHCM only)